Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2025-03-01 Director's Dealing
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "FORM 4" and "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2025-03-01 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Phillip Frost, M.D., ET AL
Report Publication Announcement Classification · 98% confidence The document is a short filing (1768 characters) submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, "Attached hereto is a report on *Interested party transaction*" and references a PDF file. This structure—a brief announcement pointing to an attached, specific report—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. While the content relates to a specific transaction, the document itself is the notification of publication, not the full transaction report.
2025-03-01 English
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial
Earnings Release Classification · 95% confidence The document is explicitly titled 'FORM 8-K' and 'CURRENT REPORT' filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Item 2.02 discusses 'Results of Operations and Financial Condition' for the quarter ended December 31, 2024, and Exhibit 99.1 is the attached 'Press Release of the Company dated February 27, 2025' which contains the detailed financial results and business highlights. A Form 8-K is used to announce major events that shareholders should know about promptly. While it contains earnings information (which might suggest ER), the primary regulatory filing structure is the Form 8-K itself. Since Form 8-K is not a specific code option, we must determine the best fit among the provided definitions. The content is a comprehensive announcement of quarterly results, operational updates, and financial condition changes, which is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR) if it were a 10-Q. However, the Form 8-K is a mandatory disclosure for material events. Given that the core purpose is announcing the results for a specific period (Q4 2024) via an attached press release, and it is not the full Annual Report (10-K) or a comprehensive Interim Report (IR), the closest functional match for the *content* being released is the Earnings Release (ER). However, the document *is* a Form 8-K, which is a general regulatory filing. Since 'Form 8-K' is not an option, and the document is a full, structured SEC filing reporting material information, it is not merely an announcement of a report (RPA) or a general regulatory filing (RNS) if a more specific category fits the content. The content strongly aligns with the release of periodic financial results. If the document were a 10-Q, it would be IR. Since it's an 8-K reporting Q4 results, ER is the most appropriate content classification among the choices, as it contains the highlights and details of the quarterly performance announcement, even though it's structured as an 8-K. The length (25k chars) confirms it's more than just a brief announcement. Q4 2024
2025-02-28 English
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial
Report Publication Announcement Classification · 95% confidence The document is a short regulatory filing (under 2,000 characters) from the Israel Securities Authority (MAGNA system) that explicitly states 'Attached hereto is a report on OPKO announcing operating and financial highlights'. It serves as a cover notice for an attached PDF (20250228Form8K_isa.pdf) rather than containing the full financial statements itself. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement. Q4 2024
2025-02-28 English
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
Earnings Release Classification · 95% confidence The document is a press release announcing the date and time for reporting Q4 2024 financial results (February 27, 2025) and providing details for the subsequent conference call and webcast. This type of announcement, which precedes the actual release of detailed financial figures (like an ER or IR), is typically classified as an Earnings Release (ER) announcement, as it sets the stage for the earnings discussion. However, the definitions provided distinguish between 'Earnings Release (ER)' (initial announcement of key highlights) and 'Call Transcript (CT)' (the full text of the call). Since this document *announces* the results and the call, it is most closely aligned with the function of an Earnings Release, even though it doesn't contain the actual results yet. Given the options, 'ER' is the most appropriate fit for an announcement detailing when financial results will be disclosed and discussed via a call. Q4 2024
2025-02-14 English
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
Regulatory Filings Classification · 99% confidence The document is a very short announcement (1869 characters) from OPKO Health, Inc., filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The core content is the headline: "OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025". It explicitly states that a report is attached ('Attached hereto is a report on...'). According to Rule 2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of another report (like earnings results), it should be classified as a Report Publication Announcement (RPA). It is not the actual Earnings Release (ER) or the full financial report.
2025-02-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.